Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 449Neoplasms, Plasma Cell 69Lymphoma, Mantle-Cell 66Recurrence 65Lymphoma 65Lymphoma, Non-Hodgkin 43Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Lymphoma, Large B-Cell, Diffuse 34Waldenstrom Macroglobulinemia 33Lymphoma, B-Cell, Marginal Zone 30Leukemia, Lymphocytic, Chronic, B-Cell 28Neoplasms 24Immunoglobulin Light-chain Amyloidosis 24Carcinoma, Non-Small-Cell Lung 24Leukemia 21Hodgkin Disease 17Hematologic Neoplasms 16Lymphoma, B-Cell 14Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 13Lymphoma, Large-Cell, Anaplastic 13Immunoblastic Lymphadenopathy 12Breast Neoplasms 12Mycosis Fungoides 11Lymphoma, T-Cell, Cutaneous 11Lymphoma, Large-Cell, Immunoblastic 11Congenital Abnormalities 11

Interventions

liposomal doxorubicin 2Zidovudine 2Vincristine 2Valganciclovir 2Rituximab 2Prednisone 2Etoposide 2Doxorubicin 2Cyclophosphamide 2tocilizumab 1tanespimycin 1siltuximab 1pomalidomide 1ibrutinib 1deltacortene 1Sirolimus 1Polymerase Chain Reaction 1Methotrexate 1Interferon-alpha 1Hyaluronoglucosaminidase 1Histological Techniques 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1CT-P10 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multi-centric Castleman's Disease × Bortezomib × Clear all
NCT00092222 2026-06-01

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡